Management of HIV-Associated Lymphoma

Introduction to Treatment Approach

The American College of Oncology recommends that patients with undetected HIV presenting with lymphoma should receive combination antiretroviral therapy (ART) concurrently with appropriate chemotherapy regimens, with careful attention to drug-drug interactions and supportive care measures 1, 2

Lymphoma diagnosis requires an excisional biopsy evaluated by an expert hematopathologist using immunohistochemistry and molecular techniques 1
Complete staging workup includes contrast-enhanced CT scan of neck, chest, abdomen, and pelvis 2
Complete staging workup includes FDG-PET/CT scan (more sensitive for extranodal disease) 2
Complete staging workup includes bone marrow biopsy 2
Complete staging workup includes CSF analysis for cytology and flow cytometry in aggressive NHL 1
HIV-associated lymphomas often present with B symptoms (fever, night sweats, weight loss) 3

ART should be initiated immediately and continued during chemotherapy for all patients with HIV-related lymphoma 1, 4
ART ensures sustained viral suppression and improves chemotherapy tolerability 4
ART ensures sustained viral suppression and improves immune recovery 4
ART ensures sustained viral suppression and improves overall patient outcomes 4
Treatment should follow recommendations for HIV-negative patients with appropriate modifications 1, 5
For Burkitt lymphoma and other aggressive NHL, full-dose intensive chemotherapy regimens are recommended, and rituximab should be included in CD20-positive lymphomas 4
For Hodgkin lymphoma, ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is preferred due to lower toxicity 5
For primary CNS lymphoma, high-dose methotrexate (3 g/m²) with rituximab and ART is recommended 6

PCP prophylaxis is strongly recommended for all patients with CD4 counts <200 cells/μL 4
Consider PCP prophylaxis even with higher CD4 counts due to expected decline during chemotherapy 4
Antiviral prophylaxis with acyclovir/valacyclovir for patients with history of HSV/VZV or CD4 <200 cells/μL 4
Consider antifungal prophylaxis with fluconazole in severely immunosuppressed patients (CD4 <100 cells/μL) 4
Prophylactic fluoroquinolones for patients undergoing intensive chemotherapy with expected prolonged neutropenia 4

Regular monitoring of HIV viral load and CD4 count 1
Regular monitoring of treatment response using appropriate imaging (CT or PET/CT) 2
Brain MRI with contrast is recommended for CNS lymphoma response assessment 4-8 weeks after chemotherapy 6